glp-1 news november 6 2025 ISPOR 2025: Exploring reasons for discontinuation Poll: 1 in 8 Adults

These future developments are fundamentally different from current commercial GLP-1 patches and would require rigorous clinical trials and regulatory approval before becoming available

The higher-dose semaglutide formulation for obesity (Wegovy, 2.4 mg weekly) can produce 10-15% weight loss, while diabetes doses typically yield more modest reductions

When semaglutide activates these pathways, some patients experience heightened sensitivity to dehydration, signaling your brain that fluid intake is needed even if your body's actual hydration status is adequate

This dual-sourcing approach is becoming more common, particularly for programmes where continuity of supply is critical